What Bisolvon 0.08% Treats: Main Uses and Benefits

Bisolvon 0.08% is commonly used for conditions involving certain distressing symptoms of the lower respiratory tract, primarily those related to the buildup of thick, stubborn mucus. Its therapeutic domain is established for the management of these symptoms. The medicine is relevant in contexts marked by increased discomfort and is typically applied to address symptom clusters that may become intense or disruptive.

The primary therapeutic benefit is in providing supportive relief for viscous phlegm and associated chest congestion, which provides support that helps ease the overall symptom burden. This is applied in addressing symptoms that create noticeable physiological strain, such as a heavy, chesty cough, which can interfere with daily functioning. The core indications include symptomatic assistance in acute respiratory episodes and in the supportive management of chronic conditions characterized by excessive, thick secretions.

“The medication is generally used to provide supportive symptomatic relief when the physical properties of respiratory mucus make it hard to expel.”

It is considered relevant in conditions characterized by periods of heightened symptoms, and may assist with the management of symptomatic discomfort associated with chronic, recurrent manifestations. The medicine provides support that contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Chesty Cough
Primary Symptom Targeted	Heavy, productive cough with difficult-to-clear phlegm
Target Conditions Frame	Acute respiratory illness and chronic bronchopulmonary conditions
Key Benefit	Supports the easing of overall symptom burden by assisting mucus clearance

Regulatory References

1. Therapeutic Goods Administration (TGA) monograph

Eligibility Map: Who Can and Cannot Use Bisolvon 0.08%?

This section defines the official population eligibility and non-eligibility rules for Bisolvon 0.08% (Bromhexine hydrochloride oral solution), based strictly on governmental regulatory documents.

Category	Regulatory Status
Populations Contraindicated	Absolute prohibition for patients with known hypersensitivity to bromhexine or any excipients. Use is prohibited in patients with a history of peptic ulceration and those with rare hereditary fructose or galactose intolerance (depending on excipients).
Age-Related Restrictions	The medicine is not recommended or contraindicated for use in children under 6 years of age. Use in adolescents and adults is generally permitted under standard labeled conditions.
Conditional Use Populations	Use requires caution in patients with severe hepatic impairment (liver disease) or severe renal failure (kidney impairment). Caution is also advised for patients with a history of gastric ulceration.
Pregnancy and Lactation	Use is not recommended during the first trimester of pregnancy as a precautionary measure due to limited safety data. The medicine is also not recommended for women who are breastfeeding.

Connection to the overall eligibility profile: Official regulatory documents establish a clear framework defining the populations eligible for use, centering on adults and adolescents without specific contraindicating conditions. Mandatory exclusions are established for hypersensitivity and peptic ulceration, while other vulnerable populations, such as young children, those with organ impairment, and pregnant or breastfeeding women, are subject to formal restrictions classified as contraindicated or not recommended.

The interaction profile for Bisolvon 0.08% (Bromhexine hydrochloride) is defined by several regulatory constraints and documented exposure modifications.

Contraindicated Combinations

The most critical restriction is the prohibited co-administration with antitussives (cough suppressants) and secretion-drying medications. This combination is formally classified as a pharmacodynamic conflict in regulatory documents, due to the risk of respiratory secretion accumulation.

Exposure-Modifying Interactions

A unique interaction is documented with certain antibiotics, including amoxicillin, erythromycin, and oxytetracycline. Official regulatory information states that Bromhexine increases the concentrations of these antibiotics specifically within the sputum and bronchopulmonary secretions.

Other Pharmacokinetic Considerations

Food Intake and Metabolism: Concomitant food intake is documented to increase Bromhexine plasma concentrations by partially inhibiting the drug's first-pass effect. Conversely, regulatory labels indicate that relevant interactions with common metabolic enzymes, such as CYP 450 2C9 or 3A4, are considered unlikely.

Population PK Notes: For specific patient populations, official warnings note that severe liver disease may lead to expected reduced clearance of the parent substance. In cases of severe renal insufficiency, the accumulation of metabolites cannot be ruled out, constraining use in these conditions.

How Bisolvon 0.08% Works

Mechanism of Mucus Viscosity Reduction

The active ingredient acts as a mucolytic agent by chemically targeting the acid mucopolysaccharide fibers within the respiratory secretions. This interaction results in the depolymerization of these fibers, leading to a reduction in the viscosity and adhesiveness of the secretions. This mechanistic change is a prerequisite for subsequent transport.

Mechanism of Fluid Secretion Stimulation and Dilution

The mechanism includes a secretolytic effect, which involves stimulating the serous cells in the respiratory glands to increase the output of thin, watery (aqueous) fluid. This increased secretion of aqueous fluid dilutes the high-viscosity mucus, contributing to the formation of a fluid layer along the airways.

Mechanism of Ciliary Beat Frequency Modulation

The drug also contributes a secretomotoric effect by promoting an increase in the beat frequency and coordination of the cilia lining the respiratory epithelium. In the presence of less viscous secretions, the modulation of ciliary beat frequency facilitates the transport of material out of the respiratory tract.

How to Use Bisolvon 0.08% Oral Solution

This section describes the administration and dosage patterns for Bisolvon 0.08% Oral Solution.

---

Administration and Standard Adult Dosing

The preparation is specifically an Oral Solution and is administered exclusively via the oral route. The dosage is defined in milligrams of the active substance, bromhexine hydrochloride.

The standard regimen for adults and adolescents over 12 years of age is typically 8 mg per dose. This dosage is taken three times daily (TID), often utilized on an as-needed basis for symptomatic episodes.

For the initial period of treatment, the dose may be temporarily raised to 16 mg taken three times daily for the first seven days of use. It is important to use the provided measuring device (cup or spoon) to ensure the administered volume of the liquid is accurate. The medicine can be taken with or without food.

---

Use Patterns and Adjustments

The medicine is designated for short-term use to manage specific symptomatic conditions. If symptoms worsen or do not show improvement within approximately seven consecutive days, the continuation of the course should be reviewed by a healthcare professional.

Age-Specific Use: The use of this 0.08% formulation is prohibited for children under 6 years of age. For children between 6 and 11 years, the standard dose of 8 mg TID is generally reserved for use only under the advice and supervision of a doctor or pharmacist.

Bisolvon 0.08%: Recent Clinical Evidence

Evidence for Use in Acute and Chronic Bronchopulmonary Diseases

Research examining Bisolvon 0.08% focuses on its use in conditions involving periods of heightened symptoms related to the lower respiratory tract when there is a buildup of thick, sticky mucus. The core evidence base consists of Randomized Controlled Trials (RCTs) and systematic reviews. Studies included patient groups with both acute respiratory episodes (like acute bronchitis) and chronic bronchopulmonary conditions. Researchers examined outcomes related to the physical discomfort of coughing, difficulty clearing airways, and changes in the physical characteristics of sputum, such as viscosity and volume.

Findings describe patterns observed in the studies where data show changes in sputum consistency and perceived ease of clearance within short-term observation periods. However, regulators and systematic reviews acknowledge that much of the foundational evidence was developed in earlier research periods, and the methodological approaches used evidence quality varies across studies when compared to modern standards.

Study Focus: Specific Chronic Conditions and Research Limitations

The research landscape also includes small-scale Randomized Controlled Trials exploring the use of this medicine in specific long-term conditions, such as bronchiectasis. Research examined outcomes related to systemic imbalance and exacerbation frequency. Data show patterns related to symptom evolution, but the available evidence is limited by the small number of applicable trials.

When considering the duration of treatment, the majority of the available research focuses on research exploring short-term symptom changes over limited observation periods. Consequently, information regarding outcomes from using the medicine over extended periods is not well characterized. Long-term effects are not fully established, as follow-up durations were limited, generally spanning only a few days up to three weeks.

Evidence in Special Populations and Key Uncertainties

Research has explored how symptoms evolved in certain specific patient populations, particularly children. However, the data for these groups remain insufficient. Systematic reviews indicate that studies involving children are highly heterogeneous (widely varying in design and population) and often involve small sample sizes. Results apply only to the populations studied.

This summary highlights key areas where the research evidence remains limited or uncertain: the relationship between measured changes in the physical properties of the sputum (making it thinner) and the subsequent overall patient-reported outcomes is not fully established across all research reviewed, and data for certain groups remain insufficient.

Key Studies & References Over-the-counter (OTC) medicine monograph: Bromhexine hydrochloride

Common questions about Bisolvon 0.08% (FAQ)

Q: Does Bisolvon 0.08% have sugar in it?

Official documents list all inactive ingredients, or excipients, used in the formulation. These ingredients may include sugar alcohols, such as maltitol or sorbitol, for sweetening. Regulatory information indicates that products containing these specific sugar alcohols can sometimes cause a laxative effect or diarrhea in some people.

Q: How quickly can I expect Bisolvon 0.08% to start working?

Clinical studies examined how the medication affects symptoms within short-term observation periods. Findings indicate that changes in sputum consistency (making it thinner) and perceived ease of clearance were observed within these short time frames. Official product information describes the medicine's effect as starting to occur soon after administration.

Q: How long does the effect of Bisolvon 0.08% last?

The active substance, bromhexine, is eliminated from the body over time. Pharmacokinetic data suggest the substance has a biological half-life of approximately 6 hours in humans. This half-life is the time it takes for the amount of active substance in the body to reduce by half.

Q: Can Bisolvon 0.08% be used at the same time as cold and flu medicine?

Regulatory documents include specific warnings about co-administration with other types of medicine. Official documents indicate that co-administration with antitussives (cough suppressants) and secretion-drying medications is prohibited. This restriction is in place because this combination may lead to an unwanted accumulation of respiratory secretions.

Q: What is the purpose of the 0.08% concentration in this formulation?

The 0.08% designation is the label-defined concentration of the active ingredient, bromhexine hydrochloride. This number confirms the specific amount of the active component contained within the oral aqueous solution vehicle. This concentration is established as the standard amount intended for therapeutic use.

Q: What are the ingredients besides the active one in Bisolvon 0.08%?

Official product information provides a complete list of all ingredients, including the active ingredient and the excipients (inactive ingredients). These excipients include various stabilizers, flavorings, and sweeteners (which may be sugar alcohols like maltitol or sorbitol) used to form the final liquid solution.

Q: Are there specific symptoms that mean I should stop using Bisolvon 0.08%?

Official regulatory information advises that the medicine be stopped immediately if any signs of a severe allergic reaction or severe skin reaction occur. These signs may include severe blistering, bleeding in the lips or mouth, or difficulty breathing. Such reactions are categorized as serious adverse events requiring immediate medical attention.

Q: What is the difference between Bisolvon and medications with codeine?

Bromhexine (the active ingredient in Bisolvon 0.08%) is classified as a mucolytic (secretolytic expectorant), meaning its purpose is to loosen and help clear mucus from the airways. Medications containing codeine are classified as antitussives, which work by suppressing the cough reflex. These two types of drugs have fundamentally different actions, and official documents prohibit their simultaneous use.

Q: Are there different forms of Bisolvon 0.08% available (e.g., tablet vs. liquid)?

The active ingredient, bromhexine hydrochloride, is used in various pharmaceutical forms authorized in different markets. While this specific product is an oral solution, the active ingredient is also available in solid forms, such as таблетs.

Q: Can the effect of Bisolvon 0.08% wear off over time?

The evidence base for this medicine mostly consists of research exploring short-term symptom changes. Studies looking at outcomes from using the medicine over extended periods are not well characterized. Regulatory reviews note that the follow-up durations in most studies were limited, generally spanning only a few days up to three weeks.

Q: Can Bisolvon 0.08% cause drowsiness or make me sleepy?

Official product information indicates the medicine is generally not known to affect the ability to drive or operate machinery when it is used as recommended and when no side effects are experienced. However, common nervous system side effects like dizziness and headache have been reported in official documents.

Q: What should I do if I miss a use of Bisolvon 0.08%?

Patient instructions provided in official documents generally advise taking the missed dose as soon as it is remembered, then returning to the regular schedule. The instructions also state that a double dose should not be taken to try to make up for the missed one.

Q: Can Bisolvon 0.08% be used for coughs in the summer?

The official use of this medicine is based on its therapeutic indication, which is the presence of symptoms like a buildup of thick, sticky mucus. Regulatory documents do not place any restriction on the use of the medicine based on seasonal factors.

Q: Does Bisolvon 0.08% contain alcohol?

The complete list of inactive ingredients, or excipients, in the formulation is specified in official product documents. These regulatory documents will confirm whether alcohol is present in the final solution.

Q: Can Bisolvon 0.08% affect my ability to drive?

Official product information states that when the medicine is used as recommended, it is generally not known to have any effect on the ability to drive or operate machinery. This assumes that a patient is not experiencing any side effects.

Q: Does Bisolvon 0.08% have any reported interactions with common pain relievers?

Official documents list specific interactions with certain antibiotics and antitussives, but generally state no known interaction with common non-opioid pain relievers. This typically applies to standard medications like paracetamol or ibuprofen.

Q: Can Bisolvon 0.08% be used if I have asthma?

Official regulatory information includes a precaution advising that individuals with existing conditions such as asthma or a persistent cough seek the advice of a healthcare professional prior to use. This is a common precaution listed in official warnings.

Q: What should I do if I think I have used too much Bisolvon 0.08%?

Official patient instructions always outline a specific procedure to follow in the event of using too much medicine. The procedure outlined in official documents generally directs the user to contact a poison control center or emergency services immediately.

Q: Is Bisolvon 0.08% suitable for individuals who are lactose intolerant?

The suitability for individuals with lactose intolerance is confirmed by checking the full inactive ingredient (excipient) list in official documents. This list explicitly confirms the presence or absence of lactose in the formulation.

Q: Is Bisolvon 0.08% suitable for people with diabetes?

Suitability for people with diabetes is determined by the specific sugar or sweetener content used in the formulation. Official product documents list the excipients, which allows for confirmation of whether the product contains components that may affect blood glucose levels.

Storage and Disposal Requirements

Official regulatory information specifies strict conditions for storing and disposing of Bisolvon 0.08% Oral Solution to maintain product quality.

Storage Conditions

The medicine must be stored in a cool, dry place where the temperature remains below 25 C (77 F). It must be actively protected from heat, moisture, and direct sunlight; therefore, storage in high-heat areas like a bathroom, near a sink, or on a window sill is prohibited. The product must be kept in its original packaging and out of the sight and reach of children (e.g., in a high, locked cupboard).

Disposal Instructions

Do not use the medicine after the expiration date printed on the pack. Unused or expired Bisolvon 0.08% must not be discarded in household trash or wastewater. The product should be returned to a pharmacist for safe, official handling and disposal according to local pharmaceutical waste requirements.